Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from Swedish Orphan Biovitrum AB ( (SE:SOBI) ) is now available.
Sobi reported a strong second quarter in 2025, with a 22% growth at constant exchange rates, driven by significant increases in haematology and immunology revenues. Key developments include the approval of Gamifant for HLH/MAS in Still’s disease and the submission of NASP for uncontrolled gout in the US. The company’s strategic portfolio saw a 65% growth, highlighting its commitment to rare diseases and strong commercial execution. Despite some challenges with Vonjo, Sobi remains focused on expanding its use and advancing its pipeline, supported by organizational restructuring to enhance support for upcoming launches.
The most recent analyst rating on (SE:SOBI) stock is a Buy with a SEK350.00 price target. To see the full list of analyst forecasts on Swedish Orphan Biovitrum AB stock, see the SE:SOBI Stock Forecast page.
More about Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB (Sobi) is a biopharmaceutical company focused on developing and delivering innovative therapies for rare diseases. The company primarily operates in the haematology and immunology sectors, with a strategic emphasis on expanding its portfolio of treatments for conditions with significant unmet medical needs.
Average Trading Volume: 325,299
Current Market Cap: SEK101.5B
For a thorough assessment of SOBI stock, go to TipRanks’ Stock Analysis page.